Christopher-Yuskaitis-md

Christopher Yuskaitis, M.D., Ph.D.

Assistant in Neurology

Instructor in Neurology

    Contact: 617-355-8656
  • Fax: 617-730-0463

"I provide families with a compassionate and comprehensive understanding of their child’s condition."

Medical Services

Specialties

  • Neurogenetic Disorders
  • Infantile Spasms

Departments

  • Neurology

Languages

  • English

Programs

  • Brain Development and Genetics Clinic
  • Epilepsy Genetics Program
To schedule an appointment: Call 617-355-8656
Christopher-Yuskaitis-md

Medicine is the intersection between science and humanity. 

My passion is bridging this gap. At the bedside, I provide families with a compassionate and comprehensive understanding of their child’s condition, and at the bench I utilize novel scientific techniques to better understand the developing brain.

Experience and Education

Education

Medical Degree

University of Alabama at Birmingham, 2011

Birmingham, AL

Internship and Residency

Boston Combined Residency Program, Boston Children's Hospital and Boston Medical Center, 2011-2013

Boston, MA

Residency in Pediatric Neurology

Boston Children's Hospital, 2013-2016

Boston, MA

Fellowship in Neurogenetics & Epilepsy Genetics

Boston Children's Hospital, 2016

Boston, MA

Professional History

My passion in child neurology is caring for patients with infantile spasms, neurogenetic conditions, and studying the underlying molecular basis for neurologic disorders. My graduate work identified misregulation of glycogen synthase kinase-3 as a potential target for therapeutic intervention in Fragile X syndrome. Since joining Boston Children’s Hospital, my work with Ann Poduri, MD, has contributed to a recent Nature paper identifying the specific de novo mutations in patients with epileptic encephalopathy. My current work involves studying several genes involved in infantile spasms, epileptic encephalopathy, and neurodevelopmental disorders. My priority is to understand how mutations in components of critical molecular pathways contribute to neurodevelopmental disorders, and to identify targets for therapeutic intervention.

Publications

Publications powered by Harvard Catalyst Profiles
  1. Johnson EL, Yuskaitis CJ, Rondeau MW, Klein JP. A Tangled Web. Neurohospitalist. 2015 Oct; 5(4):253-4.
  2. Yuskaitis CJ, Parviz M, Loui P, Wan CY, Pearl PL. Neural Mechanisms Underlying Musical Pitch Perception and Clinical Applications Including Developmental Dyslexia. Curr Neurol Neurosci Rep. 2015 Aug; 15(8):51.
  3. Winden KD, Yuskaitis CJ, Poduri A. Megalencephaly and Macrocephaly. Semin Neurol. 2015 Jun; 35(3):277-87.
  4. Poduri A, Heinzen EL, Chitsazzadeh V, Lasorsa FM, Elhosary PC, LaCoursiere CM, Martin E, Yuskaitis CJ, Hill RS, Atabay KD, Barry B, Partlow JN, Bashiri FA, Zeidan RM, Elmalik SA, Kabiraj MM, Kothare S, Stödberg T, McTague A, Kurian MA, Scheffer IE, Barkovich AJ, Palmieri F, Salih MA, Walsh CA. SLC25A22 is a novel gene for migrating partial seizures in infancy. Ann Neurol. 2013 Dec; 74(6):873-82.
  5. Allen AS, Berkovic SF, Cossette P, Delanty N, Dlugos D, Eichler EE, Epstein MP, Glauser T, Goldstein DB, Han Y, Heinzen EL, Hitomi Y, Howell KB, Johnson MR, Kuzniecky R, Lowenstein DH, Lu YF, Madou MR, Marson AG, Mefford HC, Esmaeeli Nieh S, O'Brien TJ, Ottman R, Petrovski S, Poduri A, Ruzzo EK, Scheffer IE, Sherr EH, Yuskaitis CJ, Abou-Khalil B, Alldredge BK, Bautista JF, Berkovic SF, Boro A, Cascino GD, Consalvo D, Crumrine P, Devinsky O, Dlugos D, Epstein MP, Fiol M, Fountain NB, French J, Friedman D, Geller EB, Glauser T, Glynn S, Haut SR, Hayward J, Helmers SL, Joshi S, Kanner A, Kirsch HE, Knowlton RC, Kossoff EH, Kuperman R, Kuzniecky R, Lowenstein DH, McGuire SM, Motika PV, Novotny EJ, Ottman R, Paolicchi JM, Parent JM, Park K, Poduri A, Scheffer IE, Shellhaas RA, Sherr EH, Shih JJ, Singh R, Sirven J, Smith MC, Sullivan J, Lin Thio L, Venkat A, Vining EP, Von Allmen GK, Weisenberg JL, Widdess-Walsh P, Winawer MR. De novo mutations in epileptic encephalopathies. Nature. 2013 Sep 12; 501(7466):217-21.
  6. Yuskaitis CJ, Beurel E, Jope RS. Evidence of reactive astrocytes but not peripheral immune system activation in a mouse model of Fragile X syndrome. Biochim Biophys Acta. 2010 Nov; 1802(11):1006-12.
  7. Mines MA, Yuskaitis CJ, King MK, Beurel E, Jope RS. GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism. PLoS One. 2010 Mar 16; 5(3):e9706.
  8. Yuskaitis CJ, Mines MA, King MK, Sweatt JD, Miller CA, Jope RS. Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. Biochem Pharmacol. 2010 Feb 15; 79(4):632-46.
  9. Yuskaitis CJ, Jope RS. Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. Cell Signal. 2009 Feb; 21(2):264-73.
  10. Min WW, Yuskaitis CJ, Yan Q, Sikorski C, Chen S, Jope RS, Bauchwitz RP. Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment potential. Neuropharmacology. 2009 Feb; 56(2):463-72.
  11. Show all
  12. Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res. 2007 Apr-May; 32(4-5):577-95.
To schedule an appointment: Call 617-355-8656

Locations

We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital
300 Longwood Avenue, Boston, MA 02115
For Patients: 617-355-6000 | 800-355-7944

Close